Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension

NCT03497689 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT03497689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03497689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Lead sponsor
United Therapeutics
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2019
Completion date
May 11, 2022
Enrollment
36 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension